Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human lung cancer and mesothelioma cell lines

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 1883-1889

  Roomi, M Waheed ^a   Kalinovsky, Tatiana ^a   Niedzwiecki, Aleksandra ^a   Rath, Matthias ^a  

^a Dr Rath Research Institute   (United States)

Author keywords

Lung cancer A 549 and Calu 3; Malignant mesothelioma MSTO 211H; MMP 2 and MMP 9; Nutrient mixture; TIMPs; U PA

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CANCER; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DIETARY SUPPLEMENTS; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MESOTHELIOMA; TISSUE INHIBITOR OF METALLOPROTEINASES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84876559714     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1880     Document Type: Article

References (51)

1. American Cancer Society: Lung cancer: What are the key statistics about lung cancer. http://www.cancer.org/cancer/lungcancer-non-small-cell/detailed guide/non-small cell-lung-cancer-key-statistics (Accessed 12/3/2012) Last revised: 10/12/2012.
2. American Lung Association: Lung Cancer Fact Sheet http://www.lung.org/ lung-disease/lung-cancer/resources/facts-fgures/lung-cancer-fact-sheet.html (Accessed 12/3/2012) Last revised 2012.
3. American Cancer Society: Malignant Mesothelioma. http://www. cancer.org/cancer/malignant mesothelioma/detailedguide/malig-nant-mesothelioma- survival-statistics (Accessed 12/3/2012) Last revised 9/20/2012.
4. Fidler IJ: Molecular biology of cancer: invasion and metastasis. In: Cancer: Principles and Practice of Oncology. 5th edition. De Vita VT, Hellman S and Rosenberg SA (eds). Lippincott-Raven, Philadelphia, PA, pp135-152, 1997.
5. Egeblad M and Werb Z: New functions for the matrix metal-loproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
6. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (Suppl 16): 15-18, 2002.
7. Chambers AF and Matrisian LM: Changing views on the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997. (Pubitemid 27371946)
8. Kleiner DL and Stetler-Stevenson WG: Matrix metalloprotein-ases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): S42-S51, 1999.
9. Yurchenko PD and Schitny JC: Molecular architecture of basement membranes. FASEB J 4: 1577-1590, 1990.
10. Barsky SH, Siegel GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Investig 49: 140-147, 1983. (Pubitemid 13039938)
11. Liotta LA, Tryggvason K, Garbisa A, Hart I, Foltz CM and Shafe S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980. (Pubitemid 10098769)
12. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
13. Schültz A, Schneidenbach D, Aust G, Tannpfel A, Steinert M and Wittekind C: Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumor Biol 23: 179-184, 2002. (Pubitemid 44858309)
14. Takashi M, Kazumitsu O Kazuo K, Yoshio N, Fujio N, Mamoru K, Motohiko F, Nanao N and Yukiyasu N: Analysis of circulating plasma matrix metalloproteinases (MMP) and tissue inhibitors of MMP in lung cancer patients. J Nihon Univ Med Assoc 59: 97-102, 2000.
15. Hirano H, Tsugu M, Kizaki T, Sashikata T, Yosgi Y, Okada Y and Mori H: Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens and ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med Electron Microsc 35: 16-23, 2002. (Pubitemid 34601464)
16. Edwards JC, McLaren J, Jones JL, Walker DA and O'Byrne KJ: Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 88: 1553-1559, 2003. (Pubitemid 36713781)
17. Werle B, Kotzsch M, Lah TT, Kos J, Gabrielcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt N and Harbeck N: Cathepsin B, plasminogen activator-inihbitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 24: 4147-4161, 2004. (Pubitemid 40468721)
18. Shetty S, Kumar A, Johnson A, Pueblitz S and Idell S: Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am J Physiol Lung Cell Mol Physiol 268: L972-L982, 1995.
19. Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin North Am 10: 383-392, 2001.
20. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303, 1990.
21. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
22. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW and O'Higgins NJ: Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 44: 1177-1183, 1998. (Pubitemid 28283054)
23. Henneke I, Greschus S, Saval R, Korfel M, Markart P, Mahavadi P, Schermuly RT, Wygrecka M, Strüzebecher J, Seeger W, Günther A and Ruppert C: Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med 181: 612-619, 2010.
24. Idell S, Pueblitz S, Emri S, Gungen Y, Gray L, Kumar A, Holiday D, Koenig KB and Johnson AR: Regulation of fbrin deposition by malignant mesothelioma. Am J Pathol 147: 1318-1329, 1995.
25. Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. Orthomolecular Med 7: 17-23, 1992.
26. Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
27. Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy-a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-543, 2010.
28. Roomi MW, Monterrey JC, Kalinovsky T, Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines: a correlation study. Exp Oncol 32: 243-248, 2010.
29. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: In vivo and in vitro anti-tumor effect of a unique nutrient mixture on lung cancer cell line A-549. Exp Lung Res 32: 441-453, 2006. (Pubitemid 44949861)
30. Amin ARMR, Kucek O, Khuri FR and Shin DM: Perspectives for cancer prevention with natural compounds. J Clin Oncol 27: 2712-2725, 2009.
31. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
32. Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu J N: T he blockage of high-affnity lysine binding sites of plas-minogen by EACA signifcantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta 1596: 182-192, 2002. (Pubitemid 34455046)
33. Kemberling JK, Hampton JA, Keck RW, Gomez MA and Selman SH: Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 170: 773-776, 2003. (Pubitemid 36999553)
34. Sato D and Matsushima M: Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10: 160-166, 2003. (Pubitemid 36470027)
35. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 7: 461-468, 1996. (Pubitemid 26249199)
36. Mukhtar H and Ahmed N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71: S1698-S1702, 2000.
37. Yang GY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616, 1998. (Pubitemid 28376804)
38. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65: 51-54, 1992.
39. Hara Y: Green tea: Health Benefts and Applications. Marcel Dekker, New York, NY, Basel, 2001.
40. Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. Anticancer Res 21: 213-219, 2001.
41. Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers 14: 268-271, 1999. (Pubitemid 30064181)
42. Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem 276: 20085-20092, 2001.
43. Naidu KA, Karl RC and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulinlike growth factor 1 receptor. Dig Dis Sci 48: 230-237, 2003. (Pubitemid 36232786)
44. Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 46: 354-367, 1982. (Pubitemid 12029882)
45. Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate 32: 188-195, 1997. (Pubitemid 27337953)
46. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 8: 2487-2493, 1998. (Pubitemid 28386538)
47. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005. (Pubitemid 41420895)
48. Nunez C, Ortiz de Apodaca Y and Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp 10: 368-372, 1995.
49. Kurbacher CM, Wagner U, Kolster B andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183-189, 1996. (Pubitemid 26147697)
50. Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997. (Pubitemid 27101848)
51. Roomi MW, Ivanov V, Netke SP, Niedzwiecki A and Rath M: Serum markers of the liver, heart and kidney and lipid profle and histopathology in ODS rats treated with nutrient synergy. J Am Coll Nutr 22: 77, abs. 86, 2003.